Incyte’s MINJUVI (tafasitamab) will receive funding in Ontario through the province’s Funding Accelerated for Specific Treatments (FAST) Program. This initiative allows patients with relapsed or refractory follicular lymphoma to access the therapy while formal reimbursement processes are finalized.
Third Arc Bio, a partner of Adagene, has selected its first lead candidate under an expanded collaboration. This follows a clinical agreement established in April 2026 between Incyte and Adagene to evaluate a combination therapy involving an Incyte antibody.
Institutional investors, including Baird Financial Group Inc. and HighTower Advisors LLC, increased their stakes in Incyte during the second quarter of 2026. These position changes were detailed in reports published on September 11, 2026.